Top 5 Drug Type | Count |
---|---|
Small molecule drug | 13 |
Natural Killer Cell Therapies | 1 |
mRNA vaccine | 1 |
Prophylactic vaccine | 1 |
Chemical drugs | 1 |
Target |
Mechanism PI3Kα inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date24 May 2019 |
Mechanism Akt-1 inhibitors [+4] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GSK-3β inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator [+4] |
Start Date25 Apr 2025 |
Sponsor / Collaborator [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Elraglusib ( GSK-3β ) | - | Phase 1 |
CB001(Brown University) ( CFLAR ) | Melanoma More | Preclinical |
VLV based Vaccine(CaroGen) | Liver Cancer More | Preclinical |
ADUS-100 ( STING ) | BRAF V600E Mutation-Positive Melanoma More | Preclinical |
TRAIL-NK-92 MI ( TRAIL ) | Castration-Resistant Prostatic Cancer More | Preclinical |